These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 21226265)

  • 21. Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease.
    Nidorf SM; Eikelboom JW; Thompson PL
    J Cardiovasc Pharmacol Ther; 2014 Jan; 19(1):45-52. PubMed ID: 24038016
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preprocedural statin therapy in percutaneous coronary intervention.
    Cahoon WD; Crouch MA
    Ann Pharmacother; 2007 Oct; 41(10):1687-93. PubMed ID: 17712042
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Statin-associated pleiotropy: possible beneficial effects beyond cholesterol reduction.
    Ito MK; Talbert RL; Tsimikas S
    Pharmacotherapy; 2006 Jul; 26(7 Pt 2):85S-97S; discussion 98S-101S; quiz 106S-108S. PubMed ID: 16803418
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein.
    Ridker PM; Fonseca FA; Genest J; Gotto AM; Kastelein JJ; Khurmi NS; Koenig W; Libby P; Lorenzatti AJ; Nordestgaard BG; Shepherd J; Willerson JT; Glynn RJ;
    Am J Cardiol; 2007 Dec; 100(11):1659-64. PubMed ID: 18036365
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rebound phenomenon of inflammatory response may be a major mechanism responsible for increased cardiovascular events after abrupt cessation of statin therapy.
    Li JJ; Li YS; Chen J; Yang JQ
    Med Hypotheses; 2006; 66(6):1199-204. PubMed ID: 16413682
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial.
    Nissen SE
    Am J Cardiol; 2005 Sep; 96(5A):61F-68F. PubMed ID: 16126025
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Exercise therapy for prevention of atherosclerosis].
    Sasaki J
    Nihon Rinsho; 2011 Jan; 69(1):119-24. PubMed ID: 21226271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Altering the pathophysiology of atherosclerosis: the multidimensional role of statins.
    Clearfield MB
    J Am Osteopath Assoc; 2010 Apr; 110(4 Suppl 4):S2-6. PubMed ID: 20453192
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pleiotropic effects of statins in atherosclerosis and diabetes.
    Bellosta S; Ferri N; Arnaboldi L; Bernini F; Paoletti R; Corsini A
    Diabetes Care; 2000 Apr; 23 Suppl 2():B72-8. PubMed ID: 10860194
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pleiotropic effects of statins and related pharmacological experimental approaches.
    Alegret M; Silvestre JS
    Methods Find Exp Clin Pharmacol; 2006 Nov; 28(9):627-56. PubMed ID: 17200729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Beneficial cardiovascular pleiotropic effects of statins.
    Davignon J
    Circulation; 2004 Jun; 109(23 Suppl 1):III39-43. PubMed ID: 15198965
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lipids, atherosclerosis and CVD risk: is CRP an innocent bystander?
    Nordestgaard BG; Zacho J
    Nutr Metab Cardiovasc Dis; 2009 Oct; 19(8):521-4. PubMed ID: 19695857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Basic science review: Statin therapy--Part I: The pleiotropic effects of statins in cardiovascular disease.
    Sadowitz B; Maier KG; Gahtan V
    Vasc Endovascular Surg; 2010 May; 44(4):241-51. PubMed ID: 20403949
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
    Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
    J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lipid-lowering therapy with statins for the primary and secondary prevention of cardiovascular disease.
    Lardizabal JA; Deedwania P
    Cardiol Clin; 2011 Feb; 29(1):87-103. PubMed ID: 21257102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A prospective study of pravastatin in the elderly at risk: new hope for older persons.
    Shepherd J
    Am J Geriatr Cardiol; 2004; 13(3 Suppl 1):17-24. PubMed ID: 15133425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus.
    Ridker PM
    J Am Coll Cardiol; 2007 May; 49(21):2129-38. PubMed ID: 17531663
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Does statin therapy reduce the risk of stroke? A meta-analysis].
    Sirol M; Bouzamondo A; Sanchez P; Lechat P
    Ann Med Interne (Paris); 2001 Apr; 152(3):188-93. PubMed ID: 11431579
    [TBL] [Abstract][Full Text] [Related]  

  • 39. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ; Fang CH
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Jupiter study, CRP screening, and aggressive statin therapy-implications for the primary prevention of cardiovascular disease.
    Kones R
    Ther Adv Cardiovasc Dis; 2009 Aug; 3(4):309-15. PubMed ID: 19460829
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.